文献速递肝病

非选择性β受体阻滞剂与肝硬化失代偿后较低死亡率相关:全国性目标试验模拟

Non-Selective Beta-Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation.
PubMed 文献 · Aliment Pharmacol Ther · 2026-06-22

该研究基于韩国国民健康保险服务数据库,对7725例病毒性肝炎相关肝硬化因肝性脑病、肝肾综合征、腹水或自发性细菌性腹膜炎住院的患者进行目标试验模拟,比较β受体阻滞剂使用者(n=2455)与非使用者(n=5270)。结果显示,β受体阻滞剂使用与6个月内全因死亡风险降低相关(累积死亡率7.8% vs 11.0%;调整HR 0.82,95%CI 0.68-0.97),低剂量β受体阻滞剂和卡维地洛亦显示关联,而中高剂量和普萘洛尔无统计学显著性。

要点

  • 肝硬化非出血性失代偿住院后,β受体阻滞剂使用与6个月全因死亡风险降低相关。
  • 低剂量β受体阻滞剂(HR 0.75)和卡维地洛(HR 0.55)与较低死亡率相关。
  • 中高剂量β受体阻滞剂和普萘洛尔与死亡风险的关联无统计学显著性。

核心结论

  • 在病毒性肝炎相关肝硬化非出血性失代偿事件后,非选择性β受体阻滞剂使用与6个月内全因死亡风险降低相关。

研究设计与样本

  • 利用韩国国民健康保险服务数据库,对2013-2023年因肝性脑病、肝肾综合征、腹水和/或自发性细菌性腹膜炎住院的7725例病毒性肝炎相关肝硬化患者进行目标试验模拟。
  • 比较β受体阻滞剂使用者(n=2455)与非使用者(n=5270),主要结局为6个月内全因死亡,次要结局为3个月内再住院。

主要发现

  • β受体阻滞剂使用者6个月累积死亡率为7.8%,非使用者为11.0%(调整HR 0.82,95%CI 0.68-0.97)。
  • 在不同并发症类型和患者亚组中均观察到β受体阻滞剂使用与较低全因死亡风险的关联。
  • 与未使用相比,低剂量β受体阻滞剂与较低死亡率相关(HR 0.75,95%CI 0.59-0.94),卡维地洛亦相关(HR 0.55,95%CI 0.32-0.94)。
  • 中高剂量β受体阻滞剂(HR 0.90,95%CI 0.71-1.15)和普萘洛尔(HR 0.87,95%CI 0.72-1.04)与死亡风险的关联无统计学显著性。

临床怎么用

  • 对于病毒性肝炎相关肝硬化非出血性失代偿住院患者,可考虑评估非选择性β受体阻滞剂的使用,尤其是低剂量或卡维地洛。

局限性

  • 本研究为观察性目标试验模拟,可能存在未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Non-selective beta blockers (NSBBs) are well established for the prevention of variceal bleeding; however, their potential roles beyond this indication remain a matter of debate. We investigated the clinical outcomes of beta-blocker use in patients with cirrhosis after hospitalisation for cirrhotic complications, excluding variceal bleeding. METHODS: Using the Korean National Health Insurance Service database, we conducted an emulated target trial among 7725 patients with viral hepatitis-related cirrhosis hospitalised for hepatic encephalopathy, hepatorenal syndrome, ascites, and/or spontaneous bacterial peritonitis (2013-2023), comparing beta-blocker users (n = 2455) and non-users (n = 5270). The primary outcome was all-cause death within 6 months; the secondary outcome was rehospitalisation within 3 months. RESULTS: Compared to beta-blocker non-users, those receiving beta-blocker therapy had a lower risk of all-cause death within 6 months [cumulative incidence of mortality 7.8% in beta-blocker users vs. 11.0% in non-users; adjusted hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.68-0.97]. A lower risk of all-cause death associated with beta-blocker use was observed across complication types and patient subgroups. When analysed by dose and agent, each compared with non-use, an association with lower mortality was observed for low-dose beta blockers (HR 0.75, 95% CI 0.59-0.94) and for carvedilol (HR 0.55, 95% CI 0.32-0.94), whereas associations for moderate-to-high-dose therapy (HR 0.90, 95% CI 0.71-1.15) and propranolol (HR 0.87, 95% CI 0.72-1.04) were not statistically significant. CONCLUSIONS: Non-selective beta blockers were associated with reduced mortality and a modest reduction in all-cause readmission among patients with viral hepatitis-related cirrhosis after non-bleeding decompensating events (ClinicalTrials.gov: NCT06977685).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Song BG, Lee M, Kang D, et al. Non-Selective Beta-Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation. Aliment Pharmacol Ther. 2026. PMID: 42328960. doi:10.1111/apt.70807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。